In short
Clinical trials are investigating Senicapoc in people with progressive fibrotic interstitial lung disease. These studies are looking at safety and how well it may work compared with placebo, with the main goal of measuring lung function decline over time.
Key points
- Clinical trials of Senicapoc are studying people with progressive fibrotic interstitial lung disease, a condition that causes worsening scarring in the lungs. The main trial is a Phase 2 interventional study with 140 planned participants. It compares Senicapoc plus local standard of care against placebo plus local standard of care. The main endpoint is the rate of decline in forced vital capacity, or FVC, over 26 weeks. The study is authorised and is focused on both safety and efficacy.
Trial overview
The available trial of Senicapoc is an interventional study in people with progressive fibrotic interstitial lung disease.
This trial is in Phase 2, which means it is testing whether the treatment may help and is still checking safety and benefit in a defined patient group.
The study status is Authorised, and the planned enrollment is 140 participants.
Condition and target population
The trial is focused on progressive fibrotic interstitial lung disease, a set of lung diseases where scarring in the lungs gets worse over time.
The target population is subjects with this condition, so the study is designed for people who already have progressive fibrotic interstitial lung disease rather than for the general public.
Study design and treatment groups
This is an interventional trial, meaning researchers give a study treatment and compare outcomes between groups.
Participants are assigned to Senicapoc or placebo, and both groups also receive local standard of care.
The study drug is listed as Senicapoc 30 mg by oral use, while the comparison group receives placebo by oral use.
A placebo is a look-alike treatment that does not contain the active study drug, which helps researchers see whether any change is due to the study treatment itself.
Main outcome being measured
The main endpoint is the rate of decline of FVC over 26 weeks.
FVC stands for forced vital capacity, a breathing test that shows how much air a person can blow out after taking a deep breath.
By measuring how quickly FVC goes down, the trial is trying to understand whether Senicapoc may help slow lung function loss in this disease.
The brief study summary also states that the trial is evaluating both safety and efficacy, which means it is looking at whether the treatment can be used safely and whether it may work better than placebo.
What this means for patients
For patients, this trial is mainly about whether Senicapoc can help slow worsening lung function in progressive fibrotic interstitial lung disease.
Because the study uses a placebo comparison, not everyone in the trial will receive Senicapoc, and this helps make the results more reliable.
The study is still relatively early in development, so the main goal is to learn more about how well it works and to continue collecting safety information in the planned group of 140 participants.